BioAtla (BCAB) Revenue (2020 - 2026)

BioAtla's (BCAB) quarterly Revenue came in at $6.5 million in Q2 2026, up 225.0% quarter-over-quarter from $2.0 million in Q4 2025.

Analysis

BioAtla (BCAB) Revenue (2020 - 2026) Analysis & Trends

BioAtla (BCAB) has reported Revenue for 5 consecutive years, with $6.5 million the latest figure, recorded in Q2 2026.

For the quarter ending Q2 2026, Revenue changed N/A year-over-year to $6.5 million; the trailing twelve-month figure through Jun 2026 stood at $8.5 million (down 22.73% YoY), and the FY2025 full-year result was $2.0 million, down 81.82% from the prior year.
Revenue improved to $6.5 million in Q2 2026 per BCAB's latest filing, from $2.0 million in the prior quarter.
Across five years, Revenue topped out at $11.0 million in Q3 2024 and bottomed at $2.0 million in Q4 2025.
Historically, Revenue has averaged $6.5 million across 3 years, with a median of $6.5 million in 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Amgen	236.37 Bn	222.38 Bn	7.24 Bn	10.05 Bn
2	Gilead Sciences	187.38 Bn	184.12 Bn	6.22 Bn	7.80 Bn
3	Vertex Pharmaceuticals	138.36 Bn	130.51 Bn	2.84 Bn	3.33 Bn
4	Regeneron Pharmaceuticals	85.09 Bn	77.10 Bn	3.93 Bn	4.29 Bn
5	Argenx Se	63.93 Bn	58.75 Bn	1.37 Bn	1.52 Bn
6	Moderna	58.07 Bn	52.94 Bn	52.00 Mn	145.00 Mn
7	Alnylam Pharmaceuticals	35.59 Bn	32.28 Bn	992.69 Mn	1.29 Bn
8	Biogen	32.63 Bn	31.34 Bn	1.96 Bn	2.74 Bn
9	Insmed	27.57 Bn	26.41 Bn	358.27 Mn	425.49 Mn
10	BioAtla	2.33 Mn	2.33 Mn	-	6.50 Mn

Historic Data

Download Data